[ad_1]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable
medical robotics company that offers increased functionality for those
suffering from neurological disorders and upper limb paralysis, today
announced that it has signed an agreement with Progettiamo Autonomia
Robotics (PAR) with the goal of offering MyoPro in Italy. PAR is a unit
of Progettiamo Autonomia, headquartered in Reggio Emilia, Italy, with 17
offices nationwide.
PAR’s focus is on neurological pathologies. It delivers aids and devices
for orthopedic rehabilitation, and works with clinicians to offer
patients functional recovery.
“Progettiamo Autonomia Robotics aims to become the leading robotics
company in Italy,” said Cristian Iori, Progettiamo Autonomia Robotics
CEO. “We are well known in the rehabilitation market where our focus is
innovation and we are supported with a large commercial network of
partners. Myomo offers us a great opportunity to extend our catalog,
addressing a broader range of patients and conditions and delivering
better service to rehabilitation facilities and direct to patients.”
Paul R. Gudonis, Chairman and CEO of Myomo, said, “This agreement with
PAR enables Myomo to continue to expand our footprint in Europe, where
we are already working with orthotics and prosthetics (O&P) practices
and rehabilitation facilities in Denmark, Germany and U.K. PAR
represents exactly the kind of innovative partner with whom we expect to
build a solid global business over time.”
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers expanded
mobility for those suffering from neurological disorders and upper limb
paralysis. Myomo develops and markets the MyoPro product line. MyoPro is
a powered upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering from
CVA stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is currently
the only marketed device that, sensing a patient’s own EMG signals
through non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are able to
return to work, live independently and reduce their cost of care. Myomo
is headquartered in Cambridge, Massachusetts, with sales and clinical
professionals across the U.S. For more information, please visit www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding the
Company’s future business expectations which are subject to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited to,
our plans for offering our MyoPro product in Italy, expansion of its
business in Europe and beyond. These forward-looking statements are only
predictions and may differ materially from actual results due to a
variety of factors. Our actual results could differ materially from
those anticipated in these forward looking statements for many reasons,
including, without limitation, risks related to regulatory approval and
market acceptance of our products, our ability to secure and maintain
reimbursement for our products, our ability to obtain additional funding
to sustain and grow our business, and the other risk factors contained
in our filings made with the Securities and Exchange Commission. More
information about factors that potentially could affect Myomo’s business
and financial results is included in Myomo’s filings with the Securities
and Exchange Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only as of
the date made. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or circumstances
after the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
[ad_2]
Source link
Leave A Comment
You must be logged in to post a comment.